Metabolic dysfunction‐associated fatty liver disease and risks of incident coronary artery disease and cerebrovascular disease: LIFE Study

Documenti analoghi

• Impact of metabolic dysfunction‐associated fatty liver disease on the incidence of Helicobacter pylori‐negative gastric cancer
  di: Tomoyuki Nakane, et al.
  Pubblicazione: (2024)
• Metabolic dysfunction‐associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study
  di: Tomonori Cho, et al.
  Pubblicazione: (2025)
• Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period
  di: Kazuma Mori, et al.
  Pubblicazione: (2024)
• Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Associations of serum carotenoids with cardiovascular disease mortality among patients with metabolic dysfunction‐associated steatotic liver disease
  di: Qian‐Qian Wang, et al.
  Pubblicazione: (2025)